Supplementary Figure S2 from Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Abstract

Changes from Baseline in the SPD for Target Lesions vs Best Overall Response as Assessed by IRC